Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | DRD3 | P35462 | 5/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.36 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL9470313 | 0.94 | PTGDR2 (0.40) | DRD2DRD3CHRM1DRD4PTGDR2 | |
| SCHEMBL29458425 | 0.87 | SLC6A9 (0.44) | PTGDR2ADORA2AADORA1CA1CA2 | |
| SCHEMBL14176469 | 0.84 | PTGDR2 (0.51) | PTGDR2ADORA2AADORA1CA1CA2 | |
| SCHEMBL17410657 | 0.84 | PTGDR2 (0.51) | PTGDR2ADORA2AADORA1BACE1 | |
| SCHEMBL26870524 | 0.84 | GPR84 (0.50) | PTGDR2ADORA2AADORA1CA1CA2 | |
| SCHEMBL367003 | 0.83 | DRD2 (0.42) | DRD2DRD3DRD4HTR1D | |
| SCHEMBL23790500 | 0.82 | GPR84 (0.44) | DRD2DRD3DRD4PTGDR2ADORA2A | |
| SCHEMBL15116983 | 0.81 | BACE1 (0.37) | DRD2PTGDR2ADORA2AADORA1CA1 | |
| SCHEMBL23303454 | 0.81 | LMNA (0.39) | PTGDR2ADORA2AADORA1CA1CA2 | |
| SCHEMBL31596070 | 0.81 | HTT (0.41) | DRD2DRD3CHRM1DRD4ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634447-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220135609-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMA (US) | 2022-05-05 | — | — | US | disclosed |
| US-9598454-B2 | Mannose derivatives for treating bacterial infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2016-08-18 | — | — | US | disclosed |
| EP-2935302-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Vertex Pharmaceuticals Incorporated (US) | 2015-10-28 | — | — | EP | disclosed |
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014100158-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100158-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-26 | — | — | WO | disclosed |
| US-5241044-A | Soluble poly(p-phenylene)s | EDISON POLYMER INNOVATION CORPORATION (US) | 1993-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243283-A1 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | MPI, MANBA, MAN2A1 | DRD2 3063/4885DRD3 3282/4885CHRM1 1445/4885 |
| US-20160235775-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | DRD2 3063/4885DRD3 3282/4885CHRM1 1445/4885 |
| US-20220135609-A1 | Mannose Derivatives for Treating Bacterial Infections | MPI, MANBA, MAN2A1 | DRD2 3063/4885DRD3 3282/4885CHRM1 1445/4885 |
| US-11634447-B2 | Mannose derivatives for treating bacterial infections | MPI, MANBA, MAN2A1 | DRD2 3063/4885DRD3 3282/4885CHRM1 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.